ABSTRACT & COMMENTARY

Cardiac and Paracardiac Structure in the SUMMIT Trial

Name: Relias Media
Price range: $

March 15, 2025

A cardiac magnetic resonance imaging study in a subgroup of the patients in the SUMMIT trial of tirzepatide in patients with heart failure with preserved ejection fraction has demonstrated that patients treated with tirzepatide had reduced left ventricular mass and paracardiac adipose tissue compared to placebo-treated patients, which may partially explain the reduction in heart failure events observed in the main SUMMIT trial.

Issue Date: March 15, 2025

Table of Contents

Dr. Stephen Brunton, physician editor, reports he is on the speakers bureau for AstraZeneca, the advisory board for Novo Nordisk, the speakers bureau and advisory board for Abbott Diabetes, and is a stockholder with Paracrine. The relevant financial relationships listed for this individual have been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements